MTD and DLT Evaluation
Eight patients were enrolled in phase I [5 patients in the first cohort of pembrolizumab 200 mg and cabozantinib 40 mg (2 were not evaluable for DLT due to missing ≥25% of the planned cabozantinib doses in cycle 1, not related to TRAE) and 3 patients in the second cohort of pembrolizumab 200 mg and cabozantinib 60 mg]. There were no DLTs observed. The MTD and RP2D were determined to be pembrolizumab 200 mg i.v. every 3 weeks and cabozantinib 60 mg orally daily.